We are thrilled to share the story of our collaboration with Isofol Medical AB, a pioneering biotech company committed to transforming cancer care. Isofol is dedicated to improving outcomes for patients with severe solid tumors by developing arfolitixorin, a novel folate-based therapy designed to enhance the efficacy of standard chemotherapy.

This lead candidate has shown strong potential in preclinical and clinical studies — and is now being evaluated in a Phase Ib/II study with an optimized dosing regimen.

At INITS, we have had the privilege of supporting Isofol over several years in their CMC and clinical supply activities. Here’s what Roger TELL, CMO at Isofol, shared about our partnership:

“INITS has supported Isofol for several years with CMC and clinical supply activities including audits of service providers. The collaboration has been very important for Isofol being a relatively small company with extensive work in clinical development. INITS has often acted as a link to Isofol’s service providers, and they have always shown a high presence and diligently taking care of the communication.”

We are immensely proud to support Isofol in their journey. We look forward to continuing this partnership and helping advance their clinical ambitions.

#Partnership #Biotechnology #CMC #IMP #Audit #Innovation #Biomanufacturing